Total Cost of Care for Bispecific Agents in Multiple Myeloma

Laura R. Bobolts

Total Cost of Care for Bispecific Agents in Multiple Myeloma

Interview with the Innovators, Bispecific Antibodies

Multiple Myeloma Education

Videos

Featuring:

Laura R. Bobolts, PharmD, BCOP

Senior Vice President, Clinical Strategy and Growth
OncoHealth
Pompano Beach, FL

Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS

Director, Pharmacy Operations
Florida Cancer Specialists & Research Institute
Tampa, FL

Hakan Kaya, MD

Hematologic Oncologist and Senior Partner, Cancer Care Northwest
Director, Inland Northwest Myeloma/Lymphoma & Transplant Program
Clinical Professor, Elson S. Floyd College of Medicine, Washington State University
Clinical Professor of Medicine, University of Washington School of Medicine
Spokane, WA

Lisa Raff, PharmD, MSPharm, BCPS, BCOP

Vice President, Pharmacy Services
OneOncology
Nashville, TN

Yonatan Resnick, PharmD

Director, Pharmacy Clinical Services
New England Cancer Specialists
Scarborough, ME

In this seventh installment, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, and Laura Bobolts, PharmD, BCOP, discuss total cost of care associated with bispecific agents and other multiple myeloma treatments, as well as how that compares to the outcomes being produced.

Total Cost of Care for Bispecific Agents in Multiple Myeloma

Featuring:

Related Articles

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content